On Thursday, Brazil’s federal health regulatory body Anvisa authorized the first prophylactic Covid-19 drug for use in Brazilians with immune problems (such as cancer patients or people who have received organ transplants) or who are contraindicated to take vaccines.
The antibody treatment, produced by AstraZeneca and sold under the brand name Evusheld, is engineered to be metabolized more slowly so it can stay active for months — perhaps for half a year.
Evusheld has already obtained regulatory approval in the U.S., France, Israel, Italy, Bahrain, Egypt, and the United Arab Emirates. The drug is the seventh anti-Covid treatment approved in Brazil.
Search
